Wall Street brokerages expect Pluristem Therapeutics Inc. (NASDAQ:PSTI) to announce ($0.08) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Pluristem Therapeutics’ earnings. Pluristem Therapeutics also reported earnings of ($0.08) per share during the same quarter last year. The firm is expected to announce its next quarterly earnings report on Wednesday, February 14th.
According to Zacks, analysts expect that Pluristem Therapeutics will report full-year earnings of ($0.34) per share for the current year, with EPS estimates ranging from ($0.34) to ($0.33). For the next year, analysts expect that the firm will report earnings of ($0.31) per share. Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that cover Pluristem Therapeutics.
Pluristem Therapeutics (NASDAQ:PSTI) last announced its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.08).
Shares of Pluristem Therapeutics (PSTI) opened at $1.35 on Friday. Pluristem Therapeutics has a 12-month low of $1.06 and a 12-month high of $2.12. The company has a market capitalization of $149.27, a PE ratio of -4.35 and a beta of 0.19.
Institutional investors and hedge funds have recently modified their holdings of the business. Heritage Investors Management Corp bought a new stake in Pluristem Therapeutics during the 3rd quarter worth approximately $113,000. Psagot Investment House Ltd. increased its holdings in Pluristem Therapeutics by 1,705.2% during the 3rd quarter. Psagot Investment House Ltd. now owns 129,522 shares of the biotechnology company’s stock worth $196,000 after purchasing an additional 122,347 shares in the last quarter. Finally, Jane Street Group LLC increased its holdings in Pluristem Therapeutics by 15.0% during the 3rd quarter. Jane Street Group LLC now owns 266,043 shares of the biotechnology company’s stock worth $402,000 after purchasing an additional 34,742 shares in the last quarter. 4.34% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This piece of content was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/09/pluristem-therapeutics-inc-psti-expected-to-announce-earnings-of-0-08-per-share.html.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.